每日一次与每日两次依诺肝素预防对静脉血栓栓塞症风险及临床相关出血的影响
本研究比较两个前瞻性临床试验中整形手术患者术后接受依诺肝素40 mg每日一次(94例)与每日两次(118例)预防的90天静脉血栓栓塞症和临床相关出血结局。每日两次组90天急性静脉血栓栓塞症发生率显著降低(0% vs 5.3%,p=0.012),临床相关出血非显著增加(6.8% vs 3.2%,p=0.25)。基于体重的每日两次给药可能优化抗凝获益与风险。
要点
- 每日两次依诺肝素较每日一次显著降低90天急性静脉血栓栓塞症风险(0% vs 5.3%,p=0.012)。
- 每日两次组临床相关出血非显著增加(6.8% vs 3.2%,p=0.25)。
- 基于体重每日两次依诺肝素0.4–0.5 mg/kg可能使更多患者避免抗凝不足或过度。
核心结论
- 每日两次依诺肝素在降低90天急性静脉血栓栓塞症风险方面优于每日一次。
- 每日两次依诺肝素可能增加临床相关出血,但本研究中观察到的差异无统计学意义。
- 基于体重的每日两次依诺肝素给药可能优化整形与重建手术后预防性抗凝的风险与获益。
研究设计与样本
- 比较两个前瞻性实施的临床试验,唯一差异为术后抗凝策略;试验1患者住院期间接受依诺肝素40 mg每日一次,试验2患者住院期间接受依诺肝素40 mg每日两次。
- 比较94例接受每日一次依诺肝素的患者与118例接受每日两次依诺肝素的患者。
- 研究还考察了基于体重的每日两次预防策略对达到抗Xa因子水平范围内的影响。
- 证据等级:治疗性,II级。
主要发现
- 每日两次依诺肝素组90天急性静脉血栓栓塞症发生率为0%,每日一次组为5.3%,差异显著(p=0.012)。
- 每日两次依诺肝素组90天临床相关出血发生率为6.8%,每日一次组为3.2%,差异无统计学意义(p=0.25)。
- 基于抗Xa因子水平,每日两次依诺肝素0.4–0.5 mg/kg可能使更大比例患者同时避免抗凝不足和过度抗凝。
临床怎么用
- 作者认为每日两次依诺肝素在降低90天急性静脉血栓栓塞症风险方面优于每日一次。
- 作者指出每日两次依诺肝素可能增加临床相关出血,但本研究中观察到的差异无统计学意义。
- 作者提出基于体重的每日两次依诺肝素给药可能优化整形与重建手术后预防性抗凝的风险与获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism is a life- or limb-threatening complication that occurs in plastic surgery patients. At present, the optimal dose of enoxaparin that balances the risk of venous thromboembolism and the risk of medication-related adverse drug events-specifically, bleeding-remains unknown. METHODS: This study compared pharmacodynamic and clinical outcomes, including 90-day venous thromboembolism and 90-day clinically relevant bleeding, between two prospectively performed clinical trials whose sole difference was postoperative anticoagulation strategy. Patients in trial 1 received enoxaparin 40 mg once daily for the duration of inpatient stay, and patients in trial 2 received enoxaparin 40 mg twice daily for the duration of inpatient stay. The study also examined the potential impact of a weight-based twice-daily prophylaxis strategy to achieve in-range anti-factor Xa levels. RESULTS: The study compared 94 patients who received once-daily enoxaparin to 118 patients who received twice-daily enoxaparin. Twice-daily enoxaparin was associated with a significant decrease in 90-day acute venous thromboembolism (0 percent versus 5.3 percent; p = 0.012) and a nonsignificant increase in 90-day clinically relevant bleeding (6.8 percent versus 3.2 percent; p = 0.25). Twice-daily enoxaparin at 0.4 to 0.5 mg/kg may allow an increased proportion of patients to avoid both inadequate anticoagulation and overanticoagulation, based on anti-factor Xa levels. CONCLUSIONS: Twice-daily enoxaparin is superior to once-daily enoxaparin for 90-day acute venous thromboembolism risk reduction. Twice-daily enoxaparin may increase clinically relevant bleeding, although observed differences in this study were not significant. Weight-based twice-daily enoxaparin dosing may optimize the risks and benefits of prophylactic anticoagulation after plastic and reconstructive surgery. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
引用
- Pannucci CJ, Fleming KI, Agarwal J, et al. The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding. Plast Reconstr Surg. 2018. PMID: 29649055. doi:10.1097/PRS.0000000000004517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。